Cargando…

Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases

BACKGROUND: Metastatic spread of tumor cells remains a serious problem in cancer treatment. Gene-directed enzyme/prodrug therapy mediated by tumor-homing genetically engineered mesenchymal stromal cells (MSC) represents a promising therapeutic modality for elimination of disseminated cells. Efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Matuskova, Miroslava, Kozovska, Zuzana, Toro, Lenka, Durinikova, Erika, Tyciakova, Silvia, Cierna, Zuzana, Bohovic, Roman, Kucerova, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431639/
https://www.ncbi.nlm.nih.gov/pubmed/25884597
http://dx.doi.org/10.1186/s13046-015-0149-2
_version_ 1782371380296155136
author Matuskova, Miroslava
Kozovska, Zuzana
Toro, Lenka
Durinikova, Erika
Tyciakova, Silvia
Cierna, Zuzana
Bohovic, Roman
Kucerova, Lucia
author_facet Matuskova, Miroslava
Kozovska, Zuzana
Toro, Lenka
Durinikova, Erika
Tyciakova, Silvia
Cierna, Zuzana
Bohovic, Roman
Kucerova, Lucia
author_sort Matuskova, Miroslava
collection PubMed
description BACKGROUND: Metastatic spread of tumor cells remains a serious problem in cancer treatment. Gene-directed enzyme/prodrug therapy mediated by tumor-homing genetically engineered mesenchymal stromal cells (MSC) represents a promising therapeutic modality for elimination of disseminated cells. Efficacy of gene-directed enzyme/prodrug therapy can be improved by combination of individual systems. We aimed to define the combination effect of two systems of gene therapy mediated by MSC, and evaluate the ability of systemically administered genetically engineered mesenchymal stromal cells to inhibit the growth of experimental metastases derived from human breast adenocarcinoma cells MDA-MB-231/EGFP. METHODS: Human adipose tissue-derived mesenchymal stromal cells (AT-MSC) were retrovirally transduced with fusion yeast cytosine deaminase::uracil phosphoribosyltransferase (CD::UPRT) or with Herpes simplex virus thymidine kinase (HSVtk). Engineered MSC were cocultured with tumor cells in the presence of prodrugs 5-fluorocytosin (5-FC) and ganciclovir (GCV). Combination effect of these enzyme/prodrug approaches was calculated. SCID/bg mice bearing experimental lung metastases were treated with CD::UPRT-MSC, HSVtk-MSC or both in combination in the presence of respective prodrug(s). Treatment efficiency was evaluated by EGFP-positive cell detection by flow cytometry combined with real-time PCR quantification of human cells in mouse organs. Results were confirmed by histological and immunohistochemical examination. RESULTS: We demonstrated various extent of synergy depending on tested cell line and experimental setup. The strongest synergism was observed on breast cancer-derived cell line MDA-MB-231/EGFP. Systemic administration of CD::UPRT-MSC and HSVtk-MSC in combination with 5-FC and GCV inhibited growth of MDA-MB-231 induced lung metastases. CONCLUSIONS: Combined gene-directed enzyme/prodrug therapy mediated by MSC exerted synergic cytotoxic effect and resulted in high therapeutic efficacy in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-015-0149-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4431639
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44316392015-05-15 Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases Matuskova, Miroslava Kozovska, Zuzana Toro, Lenka Durinikova, Erika Tyciakova, Silvia Cierna, Zuzana Bohovic, Roman Kucerova, Lucia J Exp Clin Cancer Res Research Article BACKGROUND: Metastatic spread of tumor cells remains a serious problem in cancer treatment. Gene-directed enzyme/prodrug therapy mediated by tumor-homing genetically engineered mesenchymal stromal cells (MSC) represents a promising therapeutic modality for elimination of disseminated cells. Efficacy of gene-directed enzyme/prodrug therapy can be improved by combination of individual systems. We aimed to define the combination effect of two systems of gene therapy mediated by MSC, and evaluate the ability of systemically administered genetically engineered mesenchymal stromal cells to inhibit the growth of experimental metastases derived from human breast adenocarcinoma cells MDA-MB-231/EGFP. METHODS: Human adipose tissue-derived mesenchymal stromal cells (AT-MSC) were retrovirally transduced with fusion yeast cytosine deaminase::uracil phosphoribosyltransferase (CD::UPRT) or with Herpes simplex virus thymidine kinase (HSVtk). Engineered MSC were cocultured with tumor cells in the presence of prodrugs 5-fluorocytosin (5-FC) and ganciclovir (GCV). Combination effect of these enzyme/prodrug approaches was calculated. SCID/bg mice bearing experimental lung metastases were treated with CD::UPRT-MSC, HSVtk-MSC or both in combination in the presence of respective prodrug(s). Treatment efficiency was evaluated by EGFP-positive cell detection by flow cytometry combined with real-time PCR quantification of human cells in mouse organs. Results were confirmed by histological and immunohistochemical examination. RESULTS: We demonstrated various extent of synergy depending on tested cell line and experimental setup. The strongest synergism was observed on breast cancer-derived cell line MDA-MB-231/EGFP. Systemic administration of CD::UPRT-MSC and HSVtk-MSC in combination with 5-FC and GCV inhibited growth of MDA-MB-231 induced lung metastases. CONCLUSIONS: Combined gene-directed enzyme/prodrug therapy mediated by MSC exerted synergic cytotoxic effect and resulted in high therapeutic efficacy in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-015-0149-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-09 /pmc/articles/PMC4431639/ /pubmed/25884597 http://dx.doi.org/10.1186/s13046-015-0149-2 Text en © Matuskova et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Matuskova, Miroslava
Kozovska, Zuzana
Toro, Lenka
Durinikova, Erika
Tyciakova, Silvia
Cierna, Zuzana
Bohovic, Roman
Kucerova, Lucia
Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases
title Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases
title_full Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases
title_fullStr Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases
title_full_unstemmed Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases
title_short Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases
title_sort combined enzyme/prodrug treatment by genetically engineered at-msc exerts synergy and inhibits growth of mda-mb-231 induced lung metastases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431639/
https://www.ncbi.nlm.nih.gov/pubmed/25884597
http://dx.doi.org/10.1186/s13046-015-0149-2
work_keys_str_mv AT matuskovamiroslava combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT kozovskazuzana combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT torolenka combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT durinikovaerika combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT tyciakovasilvia combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT ciernazuzana combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT bohovicroman combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases
AT kucerovalucia combinedenzymeprodrugtreatmentbygeneticallyengineeredatmscexertssynergyandinhibitsgrowthofmdamb231inducedlungmetastases